A
Alain M. Schoepfer
Researcher at University Hospital of Lausanne
Publications - 321
Citations - 16599
Alain M. Schoepfer is an academic researcher from University Hospital of Lausanne. The author has contributed to research in topics: Eosinophilic esophagitis & Medicine. The author has an hindex of 51, co-authored 265 publications receiving 13251 citations. Previous affiliations of Alain M. Schoepfer include University of Zurich & McMaster University.
Papers
More filters
Journal ArticleDOI
Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes.
Alain M. Schoepfer,Christoph Beglinger,Alex Straumann,Michael Trummler,Pietro Renzulli,Frank Seibold +5 more
TL;DR: Fecal calprotectin correlated closest with endoscopic disease activity, followed by Clinical Activity Index, CRP, and blood leukocytes, which emphasizes its usefulness for activity monitoring.
Journal ArticleDOI
Escalating incidence of eosinophilic esophagitis: a 20-year prospective, population-based study in Olten County, Switzerland.
Petr Hruz,Alex Straumann,Christian Bussmann,Pius Heer,Hans-Uwe Simon,Marcel Zwahlen,Christoph Beglinger,Alain M. Schoepfer +7 more
Journal ArticleDOI
Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies.
TL;DR: The PhiCal Test and IBD‐SCAN are highly accurate for discriminating IBD from IBS and ASCA and pANCA have a high specificity for IBD.
Journal ArticleDOI
Esophageal Dilation in Eosinophilic Esophagitis: Effectiveness, Safety, and Impact on the Underlying Inflammation
Alain M. Schoepfer,Nirmala Gonsalves,Christian Bussmann,Sébastien Conus,Hans-Uwe Simon,A. Straumann,Ikuo Hirano +6 more
TL;DR: Esophageal dilation is highly effective in providing long-lasting symptom relief and can be performed safely with a high degree of patient acceptance, however, dilation are associated with postprocedural pain in most patients and does not influence the underlying inflammatory process.
Journal ArticleDOI
Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis
Ikuo Hirano,Evan S. Dellon,Jennifer D. Hamilton,Margaret H. Collins,Kathryn A. Peterson,Mirna Chehade,Alain M. Schoepfer,Ekaterina Safroneeva,Marc E. Rothenberg,Gary W. Falk,Yehudith Assouline-Dayan,Qiong Zhao,Zhen Chen,Brian N. Swanson,Gianluca Pirozzi,Leda Mannent,Neil M.H. Graham,Bolanle Akinlade,Neil Stahl,George D. Yancopoulos,Allen Radin +20 more
TL;DR: In a phase 2 trial of patients with active EoE, dupilumab reduced dysphagia, histologic features of disease (including eosinophilic infiltration and a marker of type 2 inflammation), and abnormal endoscopic features, compared with placebo, and was generally well tolerated.